Sino Biopharmaceutical Ltd (HKG: 1177) has announced a second licensing agreement between its recently acquired subsidiary, F-star Therapeutics Inc. (NASDAQ: FSTX), and Japan-based Takeda Pharmaceutical Co., Ltd (TYO: 4502). The deal provides Takeda with a next-generation tumor immunotherapy bispecific antibody (BsAb), with the specific target or other molecule details undisclosed.
Terms of the Licensing Agreement
Under the terms of the agreement, F-star will receive a license fee and grant Takeda an exclusive global license to research, develop, and commercialize a BsAb cancer immunotherapy using F-star’s proprietary Fcab and mAb2 platforms. Takeda will be responsible for all research, development, and commercialization activities. While upfront and milestone payments were not disclosed, F-star will also receive royalties on any future net sales.
History of Collaboration
This is the second option exercised by Takeda under an evaluation and license agreement entered into with F-star in July 2021. The two companies previously entered into a license agreement for another BsAb in July 2022, highlighting their ongoing collaboration in the field of cancer immunotherapy.
About F-star Therapeutics
F-star is a clinical-stage biopharmaceutical company focused on the development of next-generation tumor immunotherapies. Sino Bio secured approval for its wholly owned UK subsidiary invoX Pharma Ltd to take over the UK firm from the Committee on Foreign Investment in the United States (CFIUS) earlier this month, further strengthening its global presence in the biopharmaceutical industry.-Fineline Info & Tech